Article
Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy.
JCO precision oncology - 1 Jun 2023
Aoki Yu, Nakamura Yoshiaki, Denda Tadamichi, Ohta Takashi, Esaki Taito, Shiozawa Manabu, Yamaguchi Kensei, Yamazaki Kentaro, Sunakawa Yu, Kato Takeshi, Okano Naohiro, Taniguchi Hiroya, Sato Taro, Oki Eiji, Nishina Tomohiro, Komatsu Yoshito, Matsuhashi Nobuhisa, Goto Masahiro, Yasui Hisateru, Ohtsubo Koushiro, Moriwaki Toshikazu, Takahashi Naoki, Horita Yosuke, Boku Shogen, Wakabayashi Masashi, Ikeno Takashi, Mitani Ryuta, Yuasa Mihoko, Yoshino Takayuki
Abstract excerpt
PURPOSE: Circulating tumor DNA (ctDNA) genotyping on the basis of next-generation sequencing (NGS) may guide targeted therapy for metastatic colorectal cancer (mCRC). However, the validity of NGS-based ctDNA genotyping for RAS/BRAF V600E mutation assessment and the efficacy of anti-EGFR and BRAF-targeted therapies on the basis of ctDNA results remains unclear. PATIENTS AND METHODS: The performance of NGS-based...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
